Sarepta Therapeutics, Inc. $SRPT Shares Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 95.9% in the second quarter, Holdings Channel.com reports. The institutional investor owned 490,329 shares of the biotechnology company’s stock after purchasing an additional 240,000 shares during the period. C WorldWide Group Holding A S’s holdings in Sarepta Therapeutics were worth $8,385,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after buying an additional 577,848 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Sarepta Therapeutics by 2.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after buying an additional 41,408 shares during the last quarter. EcoR1 Capital LLC lifted its stake in Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock valued at $82,480,000 after buying an additional 522,386 shares during the last quarter. Aberdeen Group plc lifted its stake in Sarepta Therapeutics by 91.1% in the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after buying an additional 592,125 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its stake in Sarepta Therapeutics by 1,736.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after buying an additional 822,799 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SRPT shares. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $19.00 to $26.00 in a research note on Wednesday. Guggenheim reduced their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday. Royal Bank Of Canada lifted their target price on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upgraded Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 target price on the stock in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company lowered their target price on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average price target of $33.75.

Sarepta Therapeutics Stock Up 15.2%

SRPT opened at $18.67 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The business has a 50 day simple moving average of $20.33 and a 200-day simple moving average of $26.23. The stock has a market capitalization of $1.82 billion, a P/E ratio of -21.46 and a beta of 0.52. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The business had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm’s quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.62 earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.